Clinical Guides
HIV Infection
A clinically focused adult and adolescent guide to confidential HIV testing, prompt linkage to antiretroviral care, prevention and Indian NACO service safeguards.
MedNext Academy | 13 min read
HIV Infection
A clinically focused adult and adolescent guide to confidential HIV testing, prompt linkage to antiretroviral care, prevention and Indian NACO service safeguards.
Summary
Human immunodeficiency virus (HIV) is a chronic viral infection that targets CD4 T lymphocytes and can lead to progressive immune dysfunction, opportunistic disease and malignancy if untreated. There is no routine curative therapy, but effective antiretroviral therapy (ART) can suppress viral replication and enable a long, healthy life. HIV is transmitted through certain sexual exposures, blood exposure, shared injecting equipment and vertical transmission during pregnancy, birth or breastfeeding; it is not transmitted by ordinary social contact, sharing food, hugging, coughing or mosquito bites.
A diagnosis begins with voluntary, confidential testing using the applicable national algorithm, pre-test information, valid consent and linkage to care. A reactive screening result is not a reason to disclose to relatives, employers or partners without consent. Confirmatory testing, baseline clinical evaluation, tuberculosis screening, hepatitis assessment, pregnancy assessment where relevant and readiness support occur promptly; they must not be used to delay lifesaving care unnecessarily. HIV status does not explain every fever, rash, weight loss or neurological symptom, and dangerous alternatives need ordinary clinical evaluation.
This guide is framed for India and uses NACO and WHO sources. It cannot replace the current NACO algorithm, ART-centre protocol, local laboratory validation, post-exposure prophylaxis pathway, child or pregnancy guideline, or an individual clinician’s judgement. Stigma-free care, consent and confidentiality are clinical safety requirements, not optional communication extras.
How Common Is It?
WHO estimates that 41.0 million people were living with HIV globally at the end of 2025, but global figures should not be substituted for India’s current prevalence, district burden or individual probability. HIV risk varies by exposure network, testing access, prevention uptake, geography and time. Prevalence in an ART centre or key-population programme is not the prevalence in a general clinic. The relevant clinical question is whether a person has had a biologically plausible exposure or symptoms that justify confidential testing, not whether they match a stereotype.
NACO is India’s national programme authority for HIV care and treatment. Its care-and-treatment programme describes a network of ART and Link ART services, yet a directory count or programme report does not guarantee that a specific medicine, viral-load test, counsellor or transport support is immediately available at every site. Service capacity and referral routes should be checked locally. Delay in diagnosis can permit tuberculosis, other opportunistic infection, severe bacterial infection, malignancy and avoidable transmission.
The public-health measure of progress also differs from the person’s care need. WHO reports global testing, ART and viral-suppression estimates, but percentages cannot establish an individual viral load or safety for a partner. A person with a new diagnosis needs non-judgmental linkage, while a person with an established diagnosis needs continuity, viral-load monitoring and a plan for treatment interruption or mobility. Indian epidemiology and access are dynamic; use current NACO surveillance and local service information for programme decisions.
Risk Factors
Risk follows exposure, not identity. Relevant exposures include condomless vaginal or anal sex with a partner of unknown or transmissible HIV status, sharing injecting equipment, unsafe blood exposure, needlestick injury, sexual assault, and vertical exposure. The probability from any exposure depends on the act, source viral load and treatment status, presence of sexually transmitted infections, mucosal injury and use of condoms, pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP). Oral sex usually carries lower risk than anal or vaginal exposure, but a careful confidential history is better than a simplistic ‘safe/unsafe’ label.
Tuberculosis, hepatitis B and C, sexually transmitted infections, substance use, depression, violence, housing instability and stigma can increase clinical vulnerability or disrupt care. They are not moral failings and should prompt offers of prevention, vaccination where indicated, mental-health support, safeguarding and social services. Pregnancy creates a time-sensitive prevention opportunity but must never be treated as a reason to coerce testing or disclosure. Ask about medicines, including PrEP, PEP, ART purchased elsewhere, tuberculosis treatment and traditional products, because interactions and resistance history matter.
In India, NACO-supported testing and ART services are central to care, but access may be shaped by travel, confidentiality concern, work, migration, document requirements, stock continuity and laboratory turnaround. Those are implementation issues to solve with the patient, not reasons to defer testing or blame missed visits. This guide does not calculate a personal transmission probability or claim that any group has a fixed risk; exposure assessment and locally current NACO pathways are required.
Diagnosis
History
Offer testing with informed consent and explain what a positive, negative or inconclusive result can mean, including window-period limitation after a recent exposure. Record date and nature of exposures, prior tests, PEP or PrEP, sexual and injecting history in the least intrusive language, symptoms of acute infection such as fever, rash, sore throat or lymphadenopathy, tuberculosis symptoms, weight loss, diarrhoea, neurological symptoms, pregnancy possibility and current medicines. Ask about safety, violence, disclosure concerns and preferred contact method privately. A person may decline testing; document the offer and provide prevention or return advice without pressure.
Examination
Measure vital signs, weight and nutritional status, and assess oral cavity, skin, lymph nodes, chest, abdomen, neurological state and genital or anal symptoms only with consent and a clinical indication. Look for fever, severe dehydration, respiratory compromise, focal neurology, meningism, altered consciousness, wasting, oral candidiasis, zoster, tuberculosis clues and sexually transmitted infection. A normal examination cannot exclude early HIV. An acutely ill person needs resuscitation and syndrome-specific tests in parallel with HIV testing; do not delay emergency treatment while seeking a label.
Investigations
Use the current NACO testing algorithm and validated assay sequence; do not diagnose HIV from symptoms, one unconfirmed reactive screen or a self-test alone. Once infection is confirmed, baseline evaluation commonly includes CD4 count, viral load according to programme pathway, full blood count, renal and liver assessment, hepatitis B and C testing, pregnancy testing where relevant, tuberculosis screening and tests directed by symptoms. Genotypic resistance testing, cryptococcal antigen, chest imaging, cultures, lumbar puncture or cancer evaluation are not universal panels; they are selected by stage, CD4 count, symptoms and service protocol. Preserve confidentiality in ordering, results handling and referral.
Differential Diagnosis
Acute HIV can resemble influenza-like viral illness, infectious mononucleosis, COVID-19, secondary syphilis, acute hepatitis, malaria, dengue, enteric fever or drug reaction depending on setting. Fever, rash, sore throat, lymphadenopathy and diarrhoea are non-specific; test based on exposure and syndrome, and investigate other urgent causes. A negative test soon after exposure may reflect the diagnostic window, so counsel about repeat testing at the interval specified by the test and NACO pathway rather than falsely reassure.
Advanced HIV can coexist with or be mistaken for tuberculosis, pneumocystis pneumonia, bacterial pneumonia, chronic diarrhoeal infection, lymphoma, cryptococcal meningitis, cerebral toxoplasmosis, hepatitis, severe bacterial sepsis, nutritional disease or medicine toxicity. CD4 count informs risk but does not diagnose a specific opportunistic infection. New headache, confusion, seizure, focal deficit, hypoxaemia, severe diarrhoea, jaundice or rash requires a focused emergency differential; do not ascribe it solely to ‘low immunity’.
Other immunosuppressed states, malignancy, corticosteroid treatment, transplant medicines, diabetes and severe malnutrition can produce similar presentations. ART adverse effects, immune reconstitution inflammatory syndrome and tuberculosis treatment interactions can complicate follow-up. The safest sequence is syndrome stabilisation, targeted microbiology or imaging, HIV confirmation or status review, and specialist input when advanced disease is suspected. A previous negative test does not exclude a new infection; a known HIV diagnosis does not make every symptom opportunistic infection.
Management
Link a confirmed diagnosis rapidly to an ART centre or qualified HIV clinician, complete an initial clinical assessment and initiate ART according to the current NACO regimen and timing guidance. WHO identifies ART as central to making HIV a manageable chronic health condition, but regimen choice requires pregnancy status, tuberculosis treatment, hepatitis B status, renal function, prior ART or PrEP exposure, potential drug interactions and available formulations. Counselling should cover daily use, expected adverse effects, appointment plan, viral-load monitoring, what to do if doses are missed and how to contact the service; it should not demand perfect readiness before care begins.
Screen for tuberculosis at every relevant encounter and evaluate symptoms promptly. Treat active tuberculosis, other opportunistic infections, hepatitis, sexually transmitted infections, mental-health conditions and substance use through the appropriate pathway. Some severe opportunistic infections require specialist-directed sequencing of ART and antimicrobial treatment, because immediate ART can be unsafe in selected central-nervous-system infections. Do not stop ART reflexively for a minor symptom, but seek urgent review for severe rash, jaundice, vomiting, neuropsychiatric change or suspected toxicity.
Prevention is part of clinical care: explain condoms, sterile injecting equipment, diagnosis and treatment of STIs, PEP after a qualifying recent exposure, PrEP where indicated and vertical-transmission prevention. Viral suppression greatly reduces sexual transmission risk; U=U communication should be accurate, non-coercive and tied to sustained viral suppression verified through clinical care. Offer partner services only with consent and attention to violence or disclosure risk. Good care includes reproductive choices, vaccination as locally indicated, nutrition, oral health and continuity during travel.
Prescribing Information
ART should be prescribed only through a clinician and regimen pathway competent to assess interactions, resistance history, pregnancy, renal and hepatic function, tuberculosis treatment and hepatitis B co-infection. NACO’s National Guidelines for HIV Care and Treatment 2021 is the Indian source for programme regimen and follow-up details; local updates can supersede a static teaching summary. This guide deliberately does not list a universal tablet combination or dose because formulations, age/weight bands, pregnancy recommendations, toxicity management and supply arrangements change. Never borrow another person’s ART, split fixed-dose combinations or stop treatment after a missed dose without advice.
Medication reconciliation is essential. Rifampicin-containing tuberculosis therapy, anticonvulsants, acid-suppressing medicines, hormonal contraception, supplements and recreational or traditional products may alter ART exposure or create toxicity. Hepatitis B co-infection requires particular care because stopping active agents can cause a hepatic flare. Renal impairment can alter nucleoside choice or dose. Severe rash with mucosal involvement, jaundice, marked abdominal pain, persistent vomiting, lactic-acidosis symptoms, severe neuropsychiatric symptoms or suspected hypersensitivity requires urgent clinical review, not internet-led substitution.
OI prophylaxis, PEP, PrEP, contraception, pregnancy prophylaxis and treatment for tuberculosis or STIs have separate eligibility and dosing rules. Follow current NACO and institutional pathways and document indication, baseline tests, interaction review and follow-up. Adherence support should solve barriers such as nausea, shift work, travel, privacy, food insecurity or refill access. It must never use threats, disclosure, withholding care or punitive monitoring. Pharmacist, ART-centre and infectious-disease consultation is appropriate for uncertainty, treatment failure, interaction complexity or interruptions.
When to Refer
Refer or transfer urgently for severe respiratory distress, hypoxaemia, sepsis, altered consciousness, new seizure, focal neurological deficit, severe headache with meningism, persistent vomiting, severe dehydration, major bleeding, jaundice with systemic illness, disseminated rash, severe drug reaction, suspected cryptococcal meningitis, suspected central-nervous-system infection or acute mental-health risk. Stabilise airway, breathing and circulation, obtain focused samples when this does not delay treatment, and communicate HIV status only to clinicians who need it for care using secure channels.
Early HIV/ART-centre referral is required after a positive test for confirmatory pathway completion, baseline assessment, ART initiation, counselling and follow-up. Specialist infectious-disease, tuberculosis, obstetric, paediatric, hepatology, renal, neurology, dermatology, oncology or mental-health referral is indicated by the syndrome, not merely by a positive status. Pregnancy, suspected vertical exposure, treatment interruption, possible failure, persistent viraemia, major adverse effect, hepatitis B/C co-infection, multidrug-resistant tuberculosis or advanced opportunistic disease deserves expert review.
The referral should include test type and dates, confirmation status, exposure or symptom timeline, current and previous ART/PrEP/PEP, CD4 and viral load with dates, tuberculosis and hepatitis evaluation, pregnancy status where relevant, medicines and allergies, observations, imaging or microbiology, treatments with times, confidentiality preference and immediate safety concerns. In India, refer to the nearest suitable NACO-linked service or higher-level emergency facility while protecting privacy. Referral should facilitate access, not force disclosure to family or employer.
Red Flags
In a person known or suspected to have HIV, severe breathlessness, hypoxaemia, fever with shock, confusion, reduced consciousness, new seizure, focal neurological signs, meningism, severe headache, visual change, persistent vomiting, severe diarrhoea with dehydration, rapidly spreading rash, mucosal erosion, jaundice, bleeding or marked weight loss requires urgent assessment. These signs may reflect opportunistic infection, sepsis, drug toxicity, malignancy or an unrelated emergency. Do not wait for CD4 or viral-load results before resuscitation and syndrome-based management.
Symptoms of tuberculosis such as persistent cough, fever, night sweats, weight loss or lymph-node enlargement need timely testing in India, but tuberculosis should not be assumed without microbiological or radiological evaluation where possible. In advanced disease, cryptococcal meningitis and cerebral toxoplasmosis are important neurological differentials; lumbar puncture, imaging and timing of ART need specialist protocols. New symptoms after ART initiation can reflect toxicity, intercurrent infection or immune reconstitution, and require examination rather than automatic cessation.
After a possible occupational or sexual blood exposure, PEP is time-sensitive and should be accessed immediately through the local pathway; do not wait for the source person’s final result if the protocol indicates treatment. A negative test after a very recent exposure may need planned repeat testing. Safeguarding is urgent when disclosure could trigger violence, housing loss, coercion or self-harm. Confidentiality protects health and follow-up; it never prevents emergency treatment or appropriate safeguarding action.
Indian Clinical Context
NACO, within the Ministry of Health and Family Welfare, is the national programme authority for HIV care and treatment in India. Its published 2021 national guideline and its current programme pages are more relevant to Indian ART initiation, referral and service linkage than an international regimen copied into local practice. WHO guidance provides global evidence and updates, but does not replace NACO algorithms, legal safeguards, procurement arrangements or a local ART-centre protocol. The current version of each local pathway must be checked at the point of care.
India’s ART and Link ART network can support free lifelong ART within the national programme, but programme-level provision does not prove a specific clinic’s same-day capacity, travel affordability, laboratory turnaround or continuity during migration. Ask discreetly about preferred contact, safe medicine storage, documentation concerns, travel and privacy. Use interpreters and written material safely; do not send HIV results or reminders through a shared phone without permission. Stigma, criminalisation fears, gender-based violence and family pressure can change the safest plan.
Co-infections and clinical priorities should reflect symptoms and local epidemiology: tuberculosis screening is central, while hepatitis, malaria, dengue, sexually transmitted infections and bacterial illness are investigated when indicated. This guide makes no claim of a universal Indian medicine stock, testing interval or outcome. Facilities without confirmation, ART initiation or advanced-disease capability should arrange prompt NACO-linked referral, provide emergency stabilisation and maintain confidentiality throughout transfer.
NMC Competency Mapping
The NMC Competency Based Medical Education Curriculum 2024 is the authoritative framework for Indian undergraduate education. HIV integrates microbiology, immunology, pathology, pharmacology, general medicine, community medicine, obstetrics, paediatrics, dermatology, psychiatry, ethics and communication. Exact codes and assessment level should be confirmed in the adopting institution’s NMC competency ledger; this draft does not invent a competency identifier.
A learner should explain HIV transmission and non-transmission, immune dysfunction, testing principles, window periods, ART purpose, opportunistic-infection risk and tuberculosis co-infection. At supervised clinical level, they should obtain a non-stigmatising exposure and symptom history, obtain consent for examination and testing, recognise acute illness, explain that one test may need algorithmic confirmation, maintain confidentiality, and make an organised referral. They should understand that a reactive result is sensitive information, not an excuse to disclose without consent.
Students must not independently diagnose HIV outside the validated algorithm, prescribe or change ART, manage PEP, decide OI prophylaxis, interpret treatment failure, disclose status to partners or family, or delay emergency care for counselling. Assessment should reward consent, confidentiality, correct risk communication, non-discriminatory language, tuberculosis screening and escalation for neurological or respiratory red flags. This mapping supports supervised learning and does not confer independent clinical practice or publication approval.
Key Exam Pearls for NEET PG
HIV is transmitted by defined sexual, blood, injecting and vertical exposures, not by casual contact, food sharing, handshakes or mosquitoes. Diagnosis uses the approved testing algorithm; a reactive screening result alone is not a diagnosis. A negative test soon after exposure may be within the window period, so counsel about repeat testing according to the assay and national pathway. Consent, confidentiality, counselling, correct results and connection to care are core testing principles.
ART is lifelong and starts through the applicable programme pathway after assessment; do not delay care with unnecessary tests, but recognise that selected advanced opportunistic infections require specialist timing decisions. Tuberculosis screening is central in Indian HIV care. CD4 count helps stage immune risk, whereas viral load assesses treatment response; neither one identifies a specific opportunistic infection. A known HIV label does not make every fever or neurological symptom an OI.
For pharmacology, avoid memorising a static universal regimen when national guidance, formulations and special populations differ. Check pregnancy, hepatitis B, renal function, tuberculosis therapy, interactions and previous ART/PrEP exposure. Severe rash, jaundice, neurological change, hypoxaemia, seizure or meningism needs urgent assessment. PEP after a qualifying exposure is time-sensitive. In an exam and at bedside, never endorse involuntary disclosure or discriminatory care; protect confidentiality and arrange NACO-linked treatment.
Frequently Asked Questions
Can HIV be acquired through sharing food, hugging, toilets, or mosquito bites?
No. HIV is not spread by ordinary social contact, sharing utensils, hugging, coughing, toilets or mosquitoes. Transmission requires specific sexual, blood, injecting or vertical exposure routes. Accurate information reduces stigma and helps people seek testing after genuine exposures rather than avoiding or discriminating against people living with HIV.
Why can a negative HIV test after a recent exposure require another test?
Every assay has a window period before it can reliably detect infection. The appropriate repeat interval depends on the test used, timing and whether PEP or PrEP was taken. A clinician or NACO testing service can explain the result and plan repeat testing; meanwhile, use prevention measures and seek urgent PEP assessment for a qualifying recent exposure.
Does a confirmed diagnosis mean treatment must wait for severe symptoms?
No. Effective ART is used to suppress viral replication and protect health before severe immune damage occurs. A qualified HIV service should link a confirmed diagnosis promptly to assessment and current NACO-directed treatment. Some advanced opportunistic infections require specialist coordination of timing, but this is not a reason for prolonged untreated infection.
Can a clinician tell a partner or employer about a patient’s HIV result without consent?
Confidentiality is fundamental. HIV results should be handled privately and disclosed only with the patient’s consent or within the applicable legal and clinical safeguarding framework. Clinicians should offer supported partner notification and assess violence or coercion risk, rather than exposing the patient to harm or making disclosure a condition of treatment.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic